| pubmed-article:21680696 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21680696 | lifeskim:mentions | umls-concept:C0334281 | lld:lifeskim |
| pubmed-article:21680696 | lifeskim:mentions | umls-concept:C0074830 | lld:lifeskim |
| pubmed-article:21680696 | lifeskim:mentions | umls-concept:C0061355 | lld:lifeskim |
| pubmed-article:21680696 | lifeskim:mentions | umls-concept:C0376315 | lld:lifeskim |
| pubmed-article:21680696 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:21680696 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:21680696 | pubmed:dateCreated | 2011-7-4 | lld:pubmed |
| pubmed-article:21680696 | pubmed:abstractText | Glucagon-like peptide-1 (GLP-1) receptor imaging is superior to somatostatin receptor subtype 2 (sst(2)) imaging in localizing benign insulinomas. Here, the role of GLP-1 and sst(2) receptor imaging in the management of malignant insulinoma patients was investigated. | lld:pubmed |
| pubmed-article:21680696 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21680696 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21680696 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21680696 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21680696 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21680696 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21680696 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21680696 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21680696 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21680696 | pubmed:issn | 1535-5667 | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:ReubiJean... | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:EllPeter JPJ | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:PerrenAurelA | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:WeberWolfgang... | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:SeufertJochen... | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:CaplinMartyn... | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:ForrerFlavioF | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:BrändleMichae... | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:WildDamianD | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:ChristEmanuel... | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:BomanjiJamshe... | lld:pubmed |
| pubmed-article:21680696 | pubmed:author | pubmed-author:KurzawinskiTo... | lld:pubmed |
| pubmed-article:21680696 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21680696 | pubmed:volume | 52 | lld:pubmed |
| pubmed-article:21680696 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21680696 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21680696 | pubmed:pagination | 1073-8 | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:meshHeading | pubmed-meshheading:21680696... | lld:pubmed |
| pubmed-article:21680696 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21680696 | pubmed:articleTitle | Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. | lld:pubmed |
| pubmed-article:21680696 | pubmed:affiliation | Institute of Nuclear Medicine, University College Hospital, London, United Kingdom. | lld:pubmed |
| pubmed-article:21680696 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21680696 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:21680696 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:21680696 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:21680696 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
